Research analysts at StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) in a research report issued on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
A number of other analysts have also recently issued reports on ACRX. Alliance Global Partners began coverage on shares of AcelRx Pharmaceuticals in a research note on Monday, October 2nd. They issued a “buy” rating and a $4.25 target price for the company. HC Wainwright reduced their price objective on shares of AcelRx Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, September 25th.
AcelRx Pharmaceuticals Stock Up 3.1 %
Hedge Funds Weigh In On AcelRx Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in AcelRx Pharmaceuticals by 1.0% during the third quarter. BlackRock Inc. now owns 1,947,140 shares of the specialty pharmaceutical company’s stock worth $407,000 after acquiring an additional 19,986 shares during the period. Renaissance Technologies LLC bought a new position in AcelRx Pharmaceuticals during the first quarter worth $27,000. Susquehanna International Group LLP bought a new position in AcelRx Pharmaceuticals during the fourth quarter worth $144,000. Values First Advisors Inc. increased its position in AcelRx Pharmaceuticals by 201.7% during the second quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock worth $136,000 after acquiring an additional 81,854 shares during the period. Finally, Cowen AND Company LLC bought a new position in AcelRx Pharmaceuticals during the third quarter worth $67,000. Institutional investors own 19.79% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.
- Five stocks we like better than AcelRx Pharmaceuticals
- How to Invest in Cannabis, Step by Step
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Most active stocks: Dollar volume vs share volume
- MarketBeat Week in Review – 11/13 – 11/17
- What is Short Interest? How to Use It
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.